Virax Biolabs’ CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

LONDON, July 16, 2026 /PRNewswire/ – Virax Biolabs Group Limited (Nasdaq: VRAX) has published a shareholder update providing context on several recent developments, including the filing of its fiscal 2026 Annual Report, the multi-country commercial supply agreement with Fosun Diagnostics for ImmuneSelect across six Southeast Asian markets, the completion of a preferred investment option exercise generating approximately $3.3 million in gross proceeds, and the restoration of Nasdaq minimum bid price compliance. The update also outlines the Company’s priorities for ViraxImmune™, ImmuneSelect and continued commercial execution. Read the full Press Release here

Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics

LONDON, July 09, 2026 /PRNewswire/ – Virax Biolabs Group Limited (NASDAQ: VRAX) (“Virax” or the “Company”) today announced that its wholly owned subsidiary, Virax Biolabs (UK) Limited, has entered into an exclusive multi-country commercial supply agreement with Fosun Diagnostics for the Company’s ImmuneSelect research-use immune profiling product line. The agreement covers six Southeast Asian markets, including Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia, and establishes a framework for immediate product supply under purchase orders, supporting near-term potential revenue opportunities and regional commercial expansion. Key highlights: Commercial supply agreement with Fosun Diagnostics covering six Southeast Asian markets, with exclusivity subject to agreed minimum purchase and performance requirements. Supports near-term potential revenue opportunities through purchase-order-driven supply of Virax’s commercially available ImmuneSelect product line Provides access to Fosun Diagnostics’ established regional commercial infrastructure and customer network. Framework supports expansion into additional products, higher-volume supply arrangements and potential OEM/private-label opportunities. Near-term commercial opportunity separate from ViraxImmune™, the Company’s in-development diagnostic platform. Read the full Press Release here

Virax Biolabs Presentation from the 19th World Immune Regulation Meeting: “Evaluation of T cell dysfunction in Post Acute Infection Syndromes”

Dr. Nigel McCracken, our Chief Operating Officer, will present on “Evaluation of T cell dysfunction in Post Acute Infection Syndromes” at the 19th World Immune Regulation Meeting (WIRM) in Davos, Switzerland today (March 12th) at 8pm in Foyer A1. For those not able to join us in Davos, you can have a look at the poster here or use the link below to download a copy for a closer look: